December 20, 2019

Pat Cotroneo
Senior Vice President and Chief Financial Officer
FIBROGEN INC
409 Illinois Street
San Francisco, CA 94158

       Re: FIBROGEN INC.
           Form 10-K for the Year Ended December 31, 2018
           Filed February 27, 2019
           File No. 001-36740

Dear Mr. Cotroneo:

        We have reviewed your December 13, 2019 response to our comment letter
and have the
following comment. In our comment, we may ask you to provide us with
information so we may
better understand your disclosure.

       Please respond to the comment within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to these comments, we may have additional
comments. Unless we note otherwise, our references to prior comments are to
comments in
our December 3, 2019 letter.

Form 10-K for the Year Ended December 31, 2018

Item 1. Business
Pamrevlumab For The Treatment of Fibrosis and Cancer
Clinical Development of Pamrevlumab, page 28

1.    We note your response to prior comment 1; however, we do not agree that
the identity of a
      serious adverse event (SAE) determined to be possibly related to
Pamrevlumab is
      immaterial to investors. Accordingly, please provide us proposed
disclosure for use in
      future filings that identifies all such events. With reference to the
third paragraph on page
      33 of your Form 10-K, please also tell us whether any of the SAEs
observed in the
      pamrevlumab arm of Study 069 were determined to be related to, or
possibly related to,
      Pamrevlumab. If so, please include such information in your proposed
disclosure.
 Pat Cotroneo
FIBROGEN INC
December 20, 2019
Page 2

       You may contact Sasha Parikh at 202-551-3627 or Rolf Sundwall at
202-551-3105 if
you have questions.



FirstName LastNamePat Cotroneo                          Sincerely,
Comapany NameFIBROGEN INC
                                                        Division of Corporation
Finance
December 20, 2019 Page 2                                Office of Life Sciences
FirstName LastName